Immuron’s IMM-124E Significantly Eases Symptoms of Chronic Colitis in Mouse Model, Company Reports

Immuron’s IMM-124E Significantly Eases Symptoms of Chronic Colitis in Mouse Model, Company Reports
Immuron’s investigational therapy IMM-124E significantly reduced intestinal inflammation in mice models of chronic colitis, the company reports. These results add to previous preclinical evidence showing the therapy to also of benefit in acute models of colitis, strengthening IMM-124E’s potential as an inflammatory bowel disease (IBD) treatment. A presentation of this data is set for the United European Gastroenterology Week conference set to take place in Vienna on October 20–24. Colitis, an inflammation of the inner lining of the colon, includes ulcerative colitis and Crohn’s disease, the two main forms of inflammatory bowel disease. Colitis results from complex interactions between the environment, genetic factors, immune responses, and the gut microbiome. Immuron’s IMM-124E is designed to decrease the activity of pro-inflammatory immune cells, called T-cells, that are linked with chronic inflammation by neutralizing the activity of lipopolysaccharides (LPS) antigens — proteins that trigger a pro-inflammatory response. LPS endotoxins have been identified as important triggers of inflammation in colitis, IBD and autoimmune diseases. IMM-124E effects may even be strengthened by the use of additional (adjuvant) treatments that promote other pathways involved in inflammation control. After onset of colitis symptoms — weight loss and inflammation of the colon — the mice were treated with oral IMM-124E. Treatment significantly eased several colitis symptoms, including the weight loss and signs of colon inflammation. Reduced
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *